Physician profile
Hooman Azmi
NPI 1588971618
$12,160.39
in general payments reported to CMS, 2019-2025
57 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $1,687 · 2021: $2,081 · 2022: $1,808 · 2023: $1,773 · 2024: $1,194 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,482 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,481.94 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,094.18 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,013.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $949.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $794.99 | 2021-2025 | Mavyret, Qulipta, Ubrelvy |
| Pfizer INC. | $720.88 | 2020-2025 | |
| Amgen INC. | $697.82 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $685.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $582.17 | 2019-2025 | Trintellix |
| Allergan, INC. | $568.25 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $509.82 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $376.39 | 2019-2022 | |
| Medtronic USA, INC. | $351.15 | 2019 | |
| Lundbeck LLC | $318.42 | 2022-2025 | Rexulti, Vyepti |
| Scilex Pharmaceuticals INC. | $258.56 | 2021-2025 | Ztlido |
| Abbott Laboratories | $243.25 | 2020-2025 | Infinity, Proclaim, Freestyle Libre 3 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hooman Azmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.